Coherus Oncology (FRA:8C5) EPS (Basic): €1.46 (TTM As of Mar. 2026)

What is Coherus Oncology EPS (Basic)?

Coherus Oncology FRA:8C5 +1.12% 44 EPS (Basic) is €1.46 as of Mar. 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 44/100 and a GF Value™ of €0.66 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Coherus Oncology's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.24. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.46.

Coherus Oncology's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.24. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €1.46.

Coherus Oncology's EPS without NRI for the three months ended in Mar. 2026 was €-0.23. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.10.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Coherus Oncology (FRA:8C5) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Coherus Oncology EPS (Basic) Related Terms

Coherus Oncology EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Coherus Oncology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology EPS (Basic) Chart

Coherus Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-3.37

-3.55

-2.32

0.24

1.22

Coherus Oncology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.45	2.23	-0.26	-0.27	-0.24

44GF Score

Coherus Oncology Inc FRA:8C5

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Coherus Oncology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Coherus Oncology's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(143.492	-	0)	/	117.143
	=	1.22

Coherus Oncology's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-33.153	-	0)	/	136.398
	=	-0.24

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.46

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of €1.46 mean?

Coherus Oncology (FRA:8C5) has a EPS (Basic) of €1.46 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Coherus Oncology and its competitors.

Is Coherus Oncology's EPS (Basic) too high?

Coherus Oncology's current EPS (Basic) is €1.46. Overall, Coherus Oncology has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Coherus Oncology's EPS (Basic) compare to CNXU and LENZ?

Coherus Oncology's EPS (Basic) of €1.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current EPS (Basic) is €1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Coherus Oncology stock overvalued right now?

Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.66, compared to a current price of €1.27 — trading 92.3% above its estimated fair value. The current EPS (Basic) is €1.46. Coherus Oncology's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current EPS (Basic) is €1.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.27 is trading 92.3% above its estimated GF Value™ of €0.66. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

EPS (Basic): €1.46
GF Value™: €0.66 vs. price of €1.27 (92.3% above fair value)
GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies CNXU LENZ FHTX CDXS SLGL ALEC OBIO CRBU VYGR ALXO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges CHRS:USA

Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website https://www.coherus.com

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

44GF Score

Get the complete analysis for FRA:8C5

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.27

Price

€0.66

GF Value

View FRA:8C5 Analysis

See EPS (Basic) data for all stocks →